Pharma Pipeline Health
200 industry sponsors, 22,477 trials (Phase 1-4, 2015+) Updated: 3/5/2026
9,611
Phase 1
Early innovation
5,933
Phase 2
Efficacy testing
5,827
Phase 3
Near approval
1,106
Phase 4
Post-market
200
Industry
Pharma sponsors
Industry sponsors only (normalized names)
| Company | Ph1 | Ph2 | Ph3 | Ph4 | Score | Status |
|---|---|---|---|---|---|---|
| AstraZeneca | 507 | 265 | 321 | 65 | 5,614 | 187R 624C 114F |
| Novartis | 218 | 355 | 296 | 98 | 5,269 | 123R 459C 213F |
| Pfizer | 496 | 202 | 195 | 53 | 4,005 | 93R 588C 164F |
| Eli Lilly | 487 | 144 | 223 | 33 | 3,957 | 129R 577C 73F |
| Bristol-Myers Squibb | 427 | 219 | 159 | 22 | 3,561 | 87R 471C 120F |
+ 195 more companies
Upgrade to Pro for full pipeline analysis across 200 pharma companies
See Pro FeaturesScore: (Ph3 × 10) + (Ph2 × 5) + (Ph1 × 2) + (Ph4 × 1) — weights near-term approvals highest
Status: R = Recruiting, C = Completed, F = Failed (Terminated/Withdrawn/Suspended)
Source: ClinicalTrials.gov